Impact Factor 2.349 | CiteScore 2.20
More on impact ›
Pediatric oncology has experienced great successes in the last 40 years, but daunting challenges must be overcome if these successes are to continue. Very few therapies used to treat childhood cancer today are targeted in nature and as a result, treatment is often accompanied by significant acute and long-term toxicities. Continued improvement in outcomes requires the development of targeted therapies that are more effective and less toxic.
We must learn how to effectively and safely integrate targeted therapies such as small molecules and immunotherapy into cytotoxic regimens to improve outcomes and/or develop these as stand-alone therapies for diseases and subgroups that have not benefited from dose intensive approaches. Effective therapies must also be made available to patients in the developing world, as regimens that are tolerable and effective in these settings.
Our ultimate goal is to provide fair and rapid peer review in order to publish scientific advances for the benefit of all members of the pediatric oncology community, from basic scientists, to clinical researchers, to caregivers.
The aim of this section is to help address these challenges by publishing quality basic science, translational studies and clinical trials in the field of pediatric oncology. In addition to primary research papers, we welcome focused reviews on recent advances and commentaries on controversial or emerging concepts.
Pediatric Oncology does not publish case reports.
Indexed in: PubMed, PubMed Central, Web of Science, Google Scholar, DOAJ, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Pediatric Oncology welcomes submissions of the following article types: Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Study Protocol, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Pediatric Oncology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Pediatric Oncology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology and Pediatrics.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com